Hepatocellular Cancer Clinical Trials

12 recruiting

Hepatocellular Cancer Trials at a Glance

16 actively recruiting trials for hepatocellular cancer are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in San Juan, Taipei, and Guangzhou. Lead sponsors running hepatocellular cancer studies include AbbVie, Asan Medical Center, and AHS Cancer Control Alberta.

Browse hepatocellular cancer trials by phase

Treatments under study

About Hepatocellular Cancer Clinical Trials

Looking for clinical trials for Hepatocellular Cancer? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatocellular Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatocellular Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Esophageal CancerPancreatic CancerGastric Cancer+2 more
University of Missouri-Columbia620 enrolled1 locationNCT02838836
Recruiting
Phase 1Phase 2

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma+4 more
Pfizer138 enrolled11 locationsNCT07227012
Recruiting
Phase 1

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaHepatocellular Cancer
National Cancer Institute (NCI)38 enrolled1 locationNCT05003895
Recruiting
Phase 1

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Hepatocellular Cancer
AbbVie232 enrolled22 locationsNCT06858813
Recruiting
Phase 2

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Hepatocellular CarcinomaHepatocellular Cancer
National Cancer Centre, Singapore60 enrolled1 locationNCT04912765
Recruiting
Phase 1

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular CarcinomaHepatocellular CancerResectable Hepatocellular Carcinoma
Jiping Wang, MD, PhD20 enrolled3 locationsNCT05701488
Recruiting
Not Applicable

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

Liver CancerCholangiocarcinomaHepatocellular Carcinoma+2 more
Montefiore Medical Center40 enrolled1 locationNCT06899152
Recruiting
Phase 2

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Pancreatic CancerBiliary Tract CancerCholangiocarcinoma+1 more
AHS Cancer Control Alberta62 enrolled1 locationNCT05451043
Recruiting

Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City

Hepatocellular Cancer (HCC)
Zhongshan People's Hospital, Guangdong, China4,500 enrolled1 locationNCT07010198
Recruiting
Phase 2

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Liver CancerHepatocellular CarcinomaHepatocellular Cancer+2 more
Asan Medical Center138 enrolled1 locationNCT05992220
Recruiting

Spanish Registry of Digestive Tumours RETUD

Pancreatic CancerRectal CancerBile Duct Cancer+3 more
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)20,000 enrolled1 locationNCT06711211
Recruiting
Phase 2

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Stage III Hepatocellular Cancer (CNLC Staging)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University35 enrolled1 locationNCT05412589
Recruiting
Phase 4

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Hepatocellular CarcinomaHepatocellular Cancer
The Methodist Hospital Research Institute24 enrolled1 locationNCT05185505
Recruiting
Not Applicable

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Breast CancerGastric CancerProstate Cancer+5 more
Hospices Civils de Lyon410 enrolled17 locationsNCT03787056
Recruiting

Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma

Quality of LifeHepatocellular CancerStereotactic Body Radiation Therapy+1 more
Ludwig-Maximilians - University of Munich100 enrolled1 locationNCT03253536
Recruiting

Utilization of 5HTT gene polymorphism as a prognostic indicator in cancer

cancer. We are recruiting patients with a known primary cancer of the following types: lymphoma, lung, gastrointestinal tumours, genitourinary tumours, hepatocellular cancer, breast, nasopharyngeal cancers). Adjustment for cancer type in the statisticall analysis will be done by including cancer type in the regression model.
University of Alexandria300 enrolled1 locationACTRN12610000028000